newest glp-1 medications for type 2 diabetes 2025 Use of glucose-lowering in the management of diabetes. American Association Standards of Care in Diabetes–2025 https://lnkd.in/eFBg5xtQ Before 1 December 2025: GLP-1

Al-Obeidi, S

The appeal of novel weight-loss compounds is understandable, but the risks of self-administering unlicensed injectables without medical oversight are substantial and should not be underestimated

The difference between the two lies not in the active ingredient, but in the dose and approved use

Semaglutide Semaglutide supports appetite regulation and improved insulin sensitivity, helping patients reduce caloric intake while maintaining nutritional balance

To ensure the groups were comparable, the team matched each patient taking GLP-1 medications to a patient not taking these medications, based on similar age, sex, and other factors